PARP1 and breast cancer: These data emphasize the crucial importance of Akt activation in PARP1 inhibition’s cytoprotective property that can lead to undermining PARP1 inhibition’s cytostatic effect on breast cancer gene (BRCA) mutations carrying cancers [110].